Study study type
PathologyT1T0Patientssample sizesROB Results

mGC or mGEJC - L2 - all population metastatic/advanced mGC or mGEJC mGC or mGEJC - 2nd Line (L2) mGC or mGEJC - L2 - all population

versus irinotecan, paclitaxel
avelumab alone
JAVELIN Gastric 300, 2018
  NCT02625623		RCTmGC or mGEJC - L2 - all populationavelumabphysician's choice of chemotherapy (paclitaxel or irinotecan)patients with unresectable, recurrent, locally advanced, or metastatic gastric cancer/gastro-oesophageal junction cancer with disease progression after second-line treatment185 / 186some concern
 inconclusive
  • inconclusive 10 % increase in deaths (OS) (PE)
  • statistically significant 73 % increase in progression or deaths (PFS)
  • statistically significant 63 % decrease in DCR
versus paclitaxel
pembrolizumab alone
KEYNOTE-061 (all population), 2018
  NCT02370498		RCTmGC or mGEJC - L2 - all populationpembrolizumabpaclitaxelpatients with advanced gastric or gastro-oesophageal junction cancer that progressed on first-line chemotherapy with a platinum and fluoropyrimidine296 / 296some concern
 inconclusive
  • statistically significant 49 % increase in progression or deaths (PFS)
versus placebo
nivolumab alone
ATTRACTION-2 (Kang), 2017
  NCT02267343		RCTmGC or mGEJC - L2 - all populationnivolumabplacebopatients with advanced gastric or gastro-oesophageal junction cancer who had been previously been treated with two or more chemotherapy regimens330 / 163low
 inconclusive
  • suggested 37 % decrease in deaths (OS) (PE)
  • suggested 38 % decrease in deaths (OS) (extension)
  • suggested 40 % decrease in PFS (extension)
  • suggested 40 % decrease in progression or deaths (PFS)
versus Standard of Care (SoC)
Ipilimumab (10 mg/kg)
CA184-162, 2017
  NCT01585987		RCTmGC or mGEJC - L2 - all populationipilimumabSoC (maintenance)patients with unresectable locally advanced/ metastatic gastric or gastroesophageal junction (GEJ) cancer who achieved at least stable disease (SD) following first-line treatment with combination platinum-fluoropyrimidine chemotherapy57 / 57some concern
 inconclusive
  • statistically significant 59 % increase in progression or deaths (PFS)
  • statistically significant 44 % increase in irPFS (PE)

mGC or mGEJC - L2 - PDL1 positive metastatic/advanced mGC or mGEJC mGC or mGEJC - 2nd Line (L2) mGC or mGEJC - L2 - PDL1 positive

versus paclitaxel
pembrolizumab alone
KEYNOTE-061 (PDL1 CPS>1), 2018
  NCT02370498		RCTmGC or mGEJC - L2 - PDL1 positivepembrolizumabpaclitaxelpatients with advanced gastric or gastro-oesophageal junction cancer that progressed on first-line chemotherapy with a platinum and fluoropyrimidine (PDL1 CPS>1 population)196 / 199some concern
 inconclusive
  • inconclusive 18 % decrease in deaths (OS) (PE)
  • statistically significant 27 % increase in progression or deaths (PFS) (PE)

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons